Translation Accelerator Core

摘要：翻译加速器核心的目标是提供适当的专业知识和 资源，以行业级别的严格要求推进斯坦福AViDD中心项目的翻译工作。 核心中嵌入了一个行业顾问联盟，该联盟将为所有关键方面提供专家支持 成功的临床前开发-从领导识别、领导优化到提名 开发候选人，以及适当的支持IND的研究。这一临床前开发包括虚拟 小分子筛选、计算化学与建模、药物化学、体外表征 药物代谢和药代动力学(DMPK)特性、配方、放大和过程化学 包括分析方法的发展、体内毒理学和药物代谢的表征以及 药代动力学(DMPK)特性和调节事务。最后，为了确保这些努力是有效和 在最大限度地提高生产率的情况下，我们汇集了三位来自行业的世界级研究主管，以及 公司组织和行业合作伙伴，其使命和资源致力于帮助 令人信服的铅分子正在走向商业化。这一核心的成功实现 将努力开发针对SARS-CoV-2的新型门诊抗病毒疗法，并 其他具有大流行潜力的RNA病毒。

ABSTRACT: The goal of the Translation Accelerator Core is to provide the appropriate expertise and resources to advance the translational efforts of the Stanford AViDD Center projects with industry-level rigor. Embedded in the Core is an Industry Consultants Consortium that will provide expert support for all key facets of successful preclinical development—from lead identification, to lead optimization, to nomination of a development candidate, and appropriate IND-enabling studies. This preclinical development includes virtual small molecule screening, computational chemistry and modeling, medicinal chemistry, in vitro characterization of drug metabolism and pharmacokinetic (DMPK) properties, formulation, scale-up and process chemistry including analytical methods development, in vivo toxicology and characterization of drug metabolism and pharmacokinetic (DMPK) properties, and regulatory affairs. Finally, to ensure these efforts are efficient and maximally productive, we have assembled a trio of world-class directors of research from industry, and incorporated organizations and industry partners whose mission and resources are dedicated to helping compelling lead molecules advance towards commercialization. Successful accomplishment of this Core’s efforts will enable the development of new classes of outpatient antiviral therapeutics for SARS-CoV-2 and other RNA viruses of pandemic potential.